Pharmaceuticals News and Research

RSS

HHS releases plan for development and purchase of medical countermeasures

HHS Secretary Mike Leavitt has released for display in the Federal Register the Department's new roadmap for developing and purchasing medical countermeasures against a host of chemical, biological, radiological and nuclear (CBRN) threats.

19 Apr 2007

ADVENTRX announces positive data from multidrug therapy with cofactor

ADVENTRX Pharmaceuticals has announced positive results from preclinical studies using a multidrug treatment regimen including ANX-510 (CoFactor) at the American Association for Cancer Research (AACR) Annual Meeting.

19 Apr 2007

Purdue molecule could lead to first drug treatment for Alzheimer's disease

A molecule designed by a Purdue University researcher could lead to the first drug treatment for Alzheimer's disease.

18 Apr 2007

OncoGenex Technologies announces data from a Phase II clinical trial of OGX-011

The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer.

18 Apr 2007

Indevus and Valera complete merger

Indevus Pharmaceuticals and Valera Pharmaceuticals have announced the completion of their previously announced merger, which became effective at 12:01 a.m., April 18, 2007.

18 Apr 2007

More effective therapies for individual cancers - personalized medicine

Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

ThromboGenics NV has announced that it has completed a global license agreement with Millipore Corporation under which ThromboGenics will exclusively license its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(x).

17 Apr 2007

Cybercitizen Health Europe

In today's world of fragmented media and channel mix, it is increasingly difficult to isolate the information sources used by consumers to research health information and inform healthcare decision making.

17 Apr 2007

Progen Pharmaceuticals announces positive results in PI-88 trial

Progen Pharmaceuticals Limited has announced the final stage 1 results of its Phase 2 trial of PI-88 in patients who had previously undergone surgical removal of liver cancer.

17 Apr 2007

Osprey Pharmaceuticals issued 3 U.S. patents

Osprey Pharmaceuticals Limited has announced that it has been granted three patents by the U.S. Patent Office.

17 Apr 2007

Pharma sales reps' productivity inhibited by unnecessary internal communication

According to a new study by pharmaceutical research and consulting firm Best Practices, LLC, pharma sales reps spend an average of 13.7 hours a week managing internal communication.

17 Apr 2007

Lilly and AACR tackle cancer together

Innovative and collaborative cancer research can be the catalyst to improving patient outcomes.

17 Apr 2007

Researchers induce cell death in leukemia

Researchers from the Virginia Commonwealth University Massey Cancer Center presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemia (CLL).

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007